CURRENT PORTFOLIO
-
SiteOne Therapeutics, Inc. (Private), where Mr. Sears is Chairman of the Board and lead investor, is developing novel non-opioid pain therapeutcs targeting the sodium ion channel 1.7 with high selectivity. SiteOne also has programs in long acting analgesics and occular pain based on Nav 1.7
-
AN2 Therapeutics, Inc. (Private), is developing a novel antibiotic therapy for a difficult to treat pulmonary infection. Phase III registration trials expected to commencet in 2021.
-
Halcyon Medical, Inc. (Private), where Mr. Sears is a lead investor and board member, has developed a novel interventional approach for the treatment of a significant refractory cardiovascular condition.
-
Coaxis Medical, Inc. (Private), Has developed instruments and fixtures for tissue approximation and anastomosis in the minimally invasive surgical setting. Coaxis has the potential to significantly reduce procedure time and improve patency.
-
CharlestonPharma, LLC (Private), where Mr. Sears is the lead investor, targets its proprietary monoclonal antibodies against nucleolin which is found on the surface of cancer cells, but not normal cells. The Company has demonstrated high levels of cidal in-vitro activity in a wide range of tumor types and has begun animal testing in preparation for an IND filing. Discussions with pharmaceutical partners on further development and commercialization are underway.
-
Cluain Eraird Equity Investors
Cluain Eraird Equity Investors, LLC (CE Equity) manages limited partnerships that invest in very small capitalization publicaly-traded U.S. companies. Mr. Sears is an advisor to CE Equity and through an affilated Trust is an investor in CE Equity and CE Equity - Very Small Cap U.S. Long, L.P.
-
Helix Ventures
Helix Ventures is a healthcare-focused venture firm focused on innovative therapeutic proudct opportunities. SCM is an adviser to the firm's Funds and through an affiliated Trust is an investor in the Helix Founders Fund, L.P.
-
UpStart Ventures LLC: Utah based UpStart Ventures is a seed/early stage venture firm. SCM is an advisor to UpStart Ventures, LLC.
Cellerant Therapeutics, Inc. (Private), is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant’s lead product, CLT-008, is in Phase 3 clinical trials in patients with hematological malignancies. The Company also has a cancer stem cell (CSC) antibody discovery program focused on therapies for acute myelogenous leukemia, multiple myeloma and myelodysplastic syndrome.
Sears Capital Management, Inc (SCMI) provides this data for informational purposes only. No warranties or representations are made about the suitability of these securities for investment by individusals or institutions. Descriptions contained herein have not been reviewed by the named companies and are solely attributable to SCMI.